๋ ๋ฏธํํ๋
**๋ ๋ฏธํํ๋(Remifentanil)**์ ํํ๋๊ณผ ๊ตฌ์กฐ์ ์ผ๋ก ์ ์ฌํ ๊ฐ๋ ฅํ๊ณ ์ด๋จ๊ธฐ ์์ฉ์ ํ๋ ํฉ์ฑ **๋ฎค-์คํผ์ค์ด๋ ์์ฉ์ **์ ๋๋ค. ์์ํ์์๋ ์ฃผ๋ก ์ ์ ๋ง์ทจ ์ ์งํต ๋ณด์กฐ์ ๋ก ์ฌ์ฉ๋๋ฉฐ, ํนํ ์์ ์ ๋งฅ๋ง์ทจ(TIVA) ํ๋กํ ์ฝ์ ์ ์ฉํฉ๋๋ค. ์ฃผ์ ์ฝ๋ฆฌํ์ ํน์ง: * **์ฅ๊ธฐ ๋ ๋ฆฝ์ ๋์ฌ**: ๊ฐ ๋์ฌ ๋ฐ ์ ์ฅ ๋ฐฐ์ค์ ์์กดํ๋ ๋๋ถ๋ถ์ ์คํผ์ค์ด๋์ ๋ฌ๋ฆฌ, ํ์ฅ, ์ ํ๊ตฌ ๋ฐ ์กฐ์ง์ ๋นํน์ด์ ์์คํ ๋ผ์์ ์ ์ํด ๋น ๋ฅด๊ฒ ๋ถํด๋ฉ๋๋ค. ๋ฐ๋ผ์ ์ฌ๊ฐํ ๊ฐ ๋๋ ์ ์ฅ ์ฅ์ ๊ฐ ์๋ ํ์์๊ฒ ๋งค์ฐ ์์ ํฉ๋๋ค. * **๋น ๋ฅธ ์์ฉ ์์ค**: ์์ฉ ์๊ฐ์ด ๋งค์ฐ ์งง์ ์ฃผ์ ๊ธฐ๊ฐ์ ๊ด๊ณ์์ด ๋น ๋ฅด๊ณ ์์ธก ๊ฐ๋ฅํ ํ๋ณต์ ๊ฐ๋ฅํ๊ฒ ํ๋ฉฐ, ๋ค๋ฅธ ์คํผ์ค์ด๋์์ ํํ ๋ณผ ์ ์๋ ์ฅ๊ธฐ๊ฐ์ ์ง์ ์์ฉ์ ์ต์ํํฉ๋๋ค. * **์ฒ์ฅ ํจ๊ณผ**: ๋ง์ทจ ๋ณด์กฐ์ ๋ก ์ฌ์ฉ๋๋ ๋ค๋ฅธ ์คํผ์ค์ด๋์ ๋ง์ฐฌ๊ฐ์ง๋ก, ์ฉ๋์ ๋๋ ค๋ ์งํต ํจ๊ณผ๊ฐ ๋ ์ด์ ํฅ์๋์ง ์๊ณ ๋ถ์์ฉ๋ง ์ฆ๊ฐํ ์ ์๋ ์ฒ์ฅ ํจ๊ณผ๋ฅผ ๋ํ๋ ๋๋ค. > **์์ ํ**: ์ฃผ์ ์ ์ค๋จํ๋ฉด ์์ ํ ์์ฌ ์งํต ํจ๊ณผ๊ฐ ์์ผ๋ฏ๋ก, ๊ธ์ฑ ๊ฐ์ฑ ์ฌ๋ง ๋ฐ ํต์ฆ์ ์๋ฐฉํ๊ธฐ ์ํด ๋ ๋ฏธํํ๋ ์ฃผ์ ์ ์ค๋จํ๊ธฐ ์ ์ ์ง์ ์๊ฐ์ด ๊ธด ์งํต์ (์: NSAIDs, ๋ถํ๋ ๋ ธ๋ฅดํ ๋๋ ๊ตญ์ ์ ๊ฒฝ ์ฐจ๋จ)๋ฅผ ํฌ์ฌํ๋ ๊ฒ์ด ํ์์ ์ ๋๋ค.
์์ฉ ๊ธฐ์ : Remifentanil acts as a selective agonist at **mu-opioid receptors** (G-protein coupled receptors) located primarily in the pain-regulating areas of the central nervous system (limbic system, spinal cord, thalamus, midbrain). **Mechanism Pathway**: Remifentanil binds to **mu-receptors** โ inhibits adenylate cyclase โ decreases intracellular cAMP โ promotes opening of potassium channels and inhibits voltage-gated calcium channels โ hyperpolarization of nociceptive neurons โ suppression of substance P release and profound analgesia. **Metabolism**: It is rapidly metabolized via hydrolysis of its propanoic acid-methyl ester linkage by **nonspecific blood and tissue esterases** (not plasma pseudocholinesterase). The principal carboxylic acid metabolite (GR90291) is virtually inactive (4000 times less potent in dogs).
๋๋ฌผ ์ข ๋ณ ์ฉ๋
- Analgesic adjunct to general anesthesia ยท 0.2 micrograms/kg/minute (for OHE) to 0.3 micrograms/kg/minute (to reduce stimulus-induced movement) ยท IV ยท CRI ยท In propofol-anesthetized (0.3 mcg/kg/min) cats.
- Analgesic adjunct to general anesthesia ยท 4 micrograms/kg bolus IV, followed by 6-20 micrograms/kg/hr CRI. ยท IV ยท CRI ยท Do not confuse mcg/kg/hr with mcg/kg/min.
- Analgesic adjunct to general anesthesia ยท 1 microgram/kg IV loading dose slowly over 2-3 minutes, followed by a 0.1-0.2 microgram/kg/minute CRI. ยท IV ยท CRI ยท Do not confuse mcg/kg/hr with mcg/kg/min.
์ฉ๋์ ๋ฉดํ ์์ ์ ๋ฌธ๊ฐ๋ฅผ ์ํ ์์ ์ฐธ๊ณ ์๋ฃ์ ๋๋ค. ํญ์ ์ต์ ๋ผ๋ฒจ๊ณผ ๊ฐ๋ณ ํ์์ ๋ํด ํ์ธํ์ญ์์ค.
ํฌ์ฌ ๊ฒฝ๋ก
๊ธ๊ธฐ
- Hypersensitivity to remifentanil or other fentanyl analogs
- Epidural or intrathecal administration (contraindicated due to the presence of glycine in the formulation)
์ด์๋ฐ์
- Respiratory depression
- Apnea
- Bradyarrhythmias
- Hypotension
- Hyperthermia (noted in cats)
- Anaphylaxis (rare)
์ฝ๋ฌผ ์ํธ์์ฉ
- CNS Depressants (e.g., propofol, isoflurane, thiopental) ยท Additive CNS and respiratory depression; remifentanil significantly reduces MAC and induction agent requirements.
- Diuretics ยท Opiates may decrease diuretic efficacy in patients with congestive heart failure.
- Monoamine Oxidase Inhibitors (e.g., amitraz, selegiline) ยท Severe and unpredictable opiate potentiation may occur; use is generally not recommended if an MAOI has been used within 14 days.
- Skeletal Muscle Relaxants ยท Remifentanil may enhance neuromuscular blockade.
- Nitrous Oxide ยท High doses of remifentanil combined with nitrous oxide may cause cardiovascular depression.
- Tricyclic Antidepressants (e.g., clomipramine, amitriptyline) ยท May exacerbate the effects of tricyclic antidepressants.
- Warfarin ยท Opiates may potentiate anticoagulant activity.
๋ชจ๋ํฐ๋ง
- Cardiac rate and rhythm (ECG)
- Respiratory rate and depth / Capnography (ETCO2)
- Pulse oximetry (SpO2) or arterial blood gas
- Blood pressure (direct or indirect)
- Body temperature (especially in cats)
๊ณผ์ฉ๋
Overdosage manifests as an enhancement of the drug's pharmacological effects. **Clinical Signs**: * Apnea and severe respiratory depression * Chest-wall rigidity * Hypoxemia * Hypotension and severe bradycardia * Seizures **Treatment**: 1. **Discontinue drug administration immediately.** 2. Provide supportive therapy, primarily **mechanical ventilation** and oxygen administration. Because the drug is cleared so rapidly by tissue esterases, this is often the only intervention required. 3. Administer IV fluids, and use **glycopyrrolate or atropine** to manage bradycardia or hypotension. 4. **Naloxone** may be used to reverse mu-opioid activity, but caution is advised as it can lead to acute pain and sympathetic hyperactivity.
VetSheet ์ฝ๋ฌผ ๋ ํผ๋ฐ์ค๋ ๋ฉดํ ์์ ์ ๋ฌธ๊ฐ๋ฅผ ์ํ ์์ ์์ฌ๊ฒฐ์ ๋ณด์กฐ ๋๊ตฌ์ด๋ฉฐ, ์ ๋ฌธ์ ํ๋จ์ด๋ ์ ์กฐ์ฌ์ ์ต์ ๋ผ๋ฒจ์ ๋์ ํ์ง ์์ต๋๋ค.